https://pepsreview.com/articles/fda-clears-eli-lilly-once-weekly-insulin-new-front-against-novo-nordisk PepsReview en 2026-09-24 Eli Lilly, once-weekly insulin, FDA approval, Novo Nordisk, efsitora alfa, basal insulin, insulin icodec, metabolic research https://pepsreview.com/articles/cureus-faers-musculoskeletal-signals-glp-1-study-2026 PepsReview en 2026-09-23 FAERS, semaglutide safety, tirzepatide adverse events, liraglutide, musculoskeletal signals, pharmacovigilance, GLP-1 side effects, incretin safety https://pepsreview.com/articles/viking-vk2735-monthly-maintenance-dosing-trial-2026 PepsReview en 2026-09-23 VK2735, Viking Therapeutics, GLP-1 maintenance dosing, weight loss maintenance, monthly GLP-1 dosing, obesity clinical trial, GLP-1/GIP agonist https://pepsreview.com/articles/roche-enicepatide-phase-2-diabetes-trial-results PepsReview en 2026-09-23 enicepatide, Roche, CT-388, GLP-1 GIP agonist, phase 2 diabetes trial, weight loss, incretin, type 2 diabetes https://pepsreview.com/articles/fda-warning-letter-empower-pharmacy-glp-1-production-2026 PepsReview en 2026-09-23 FDA warning letter, Empower Pharmacy, compounded GLP-1, semaglutide, tirzepatide, 503B outsourcing facility, peptide testing https://pepsreview.com/articles/20-state-ags-urge-tighter-glp-1-green-list-oversight PepsReview en 2026-09-22 GLP-1, Green List, FDA import alert, compounded semaglutide, API sourcing, state attorneys general, peptide testing, pharmaceutical supply chain https://pepsreview.com/articles/fda-import-ban-hits-sinopep-subsidiary-suspending-chinese-peptide-api-sales PepsReview en 2026-09-22 Sinopep, FDA import ban, peptide API, Chinese peptide suppliers, semaglutide API, import alert, peptide supply chain, peptide testing